

PRESS RELEASE

MabGenesis announces collaboration with MSD Animal Health to discover and develop novel monoclonal antibodies for use in companion animals

Yokohama, Japan, February 13, 2025 – MabGenesis, a private biopharmaceutical company headquartered in Yokohama, Japan, and MSD Animal Health, a global leader in animal health, today announced that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential companion animal therapeutic treatments. MSD Animal Health is a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK).

Under the agreement, MabGenesis will apply its unique platform to the discovery of candidate antibodies. MSD Animal Health will have the right to develop and commercialize products resulting from the collaboration. Terms of the agreement were not disclosed.

“We are excited to partner with global animal health leader MSD Animal Health as we feel we bring complementary expertise to this collaboration,” said Katsuhiro Shinjo, DVM, PhD, Chief Executive Officer of MabGenesis. “The combination of our innovative discovery platform, MOURA Library and IMPACT, and MSD Animal Health’s capability and industry leadership has the potential for the discovery of innovative therapeutic antibodies bringing benefits to companion animal health.”

“As an industry leader with vast research knowledge and scientific expertise, MSD Animal Health looks forward to collaborating with MabGenesis as we continue to broaden our existing portfolio with industry-leading medicines, vaccines and technology solutions,” said Jim McIntyre, vice president, Global Business Development, MSD Animal Health. “Through this partnership, we hope to leverage our experience in species-specific monoclonal antibody research to enable breakthrough innovations, which may provide enhanced health benefits for companion animal health and welfare.”

About MabGenesis Inc.

MabGenesis is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate species-specific monoclonal antibodies rapidly and efficiently. MabGenesis is a private company headquartered in Yokohama, Japan.

For more information, visit <https://mabgenesis.com/en> and connect with us on [LinkedIn](#).

MabGenesis Inc. press contact

Yuichiro Shibazaki – Chief Business Officer
Email: info@mabgenesis.com
Phone: + 81 80 5926 4677

About MSD Animal Health

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals[®], MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on [LinkedIn](#) and [X \(formerly Twitter\)](#).

MSD Animal Health press contacts

Gail Thornton
Email : gail.thornton@msd.com
Phone : +1 908 392 3420

Michael Close
Email: michael.l.close@msd.com
Phone: +1 310 617-1067
